Point Mutation Cell Line Construction Services

Inquiry

As a preclinical CRO specializing in oncology, Alfa Cytology offers point mutation cell line construction services utilizing CRISPR/Cas9-mediated homologous recombination to precisely introduce single-nucleotide mutations, including missense, nonsense, and synonymous mutations, into target genomic loci. By generating isogenic cellular models that faithfully recapitulate patient-specific oncogenic or drug-resistant mutations, we provide reliable tools for your targeted therapy screening, resistance mechanism studies, and precision oncology research.

Introduction to Point Mutation Cell Line Construction

Point mutation cell lines are engineered cellular models in which specific single nucleotides or short nucleotide sequences (typically ≤ 30 bp) are precisely modified at defined genomic loci via base substitutions, insertions, or deletions. In contrast to gene knockout, which disrupts gene function through frameshift mutations, point mutation technologies enable the precise introduction of genetic alterations that mimic clinically relevant mutations while preserving the overall structural integrity and regulatory context of the target gene. These cell lines are typically generated through CRISPR/Cas9-mediated homology-directed repair (HDR), a process that involves three core components: (1) an sgRNA-guided Cas9 nuclease to induce a double-strand break (DSB) at the target site; (2) a donor DNA template (usually a single-stranded oligodeoxynucleotide, ssODN) carrying the desired mutation flanked by homology arms; and (3) the endogenous HDR machinery of the host cell, which repairs the DSB and incorporates the mutation into the genome. Leveraging the aforementioned technical advantages, point mutation cell lines have become indispensable tools in oncology research, with applications spanning the following key areas:

Clinical Resistance Modeling

Introducing clinically relevant mutations (e.g., EGFR T790M in lung cancer, KRAS G12D in colorectal cancer, BRAF V600E in melanoma) to study drug resistance mechanisms and evaluate next-generation therapeutics.

Disease Modeling

Generating isogenic cell lines that differ only at the target locus to model patient-specific oncogenic mutations and study their functional consequences.

Drug Target Validation

Assessing the functional impact of specific mutations on drug sensitivity or resistance to guide therapeutic strategies.

Genetic Disease Modeling

Recapitulating pathogenic mutations (both homozygous and heterozygous configurations) to study disease mechanisms.

Fig. 1 Aptamer dimer point mutation assay in HeLa cells. Fig. 1 Apdimer construction and comparison of switching performances of two point mutations in the tetracycline aptamer in HeLa cells. (Hedwig V, et al.; 2026)

Our Services

With an in-depth understanding of CRISPR gene editing, HDR optimization, and emerging editing technologies, Alfa Cytology provides professional point mutation cell line construction services dedicated to translating your precise mutation requirements into stable, well-characterized cellular models.

Leveraging our extensive experience in mutation strategy design, including sgRNA optimization, donor vector design, HDR enhancer application (e.g., RS-1, SCR7), and cell cycle synchronization, we ensure that every point mutation cell line exhibits precise editing, proper genotype (homozygous or heterozygous), and stable genetic characteristics, providing reliable cellular tools for your oncology research programs.

Service Details

Service Step	Service Details	Turnaround Time
Mutation Strategy Design	Design 2–3 sgRNAs targeting the mutation site with optimal cutting efficiency and minimal off-target risk. Design donor template (ssODN for small mutations ≤200 bp) containing the desired mutation. Assess cutting-to-mutation distance (optimal ≤10 bp for ssODN).	1–2 weeks
Donor Template and Vector Construction	Synthesis of ssODN or dsDNA donor templates with homology arms Design of silent mutations to disrupt PAM sequence if needed Sequence verification of all constructs	2–3 weeks
Cell Transfection and HDR Induction	Co-deliver CRISPR/Cas9 components (plasmid or RNP) and donor templates via lipid-based or electroporation methods. Optimize HDR efficiency using enhancer molecules or cell cycle synchronization when necessary.	2–3 weeks
Single-Cell Isolation	Isolate single cells into 96-well plates via limiting dilution or FACS sorting to ensure monoclonality and enable screening of correctly edited clones.	1 week
Clone Screening and Genotype Confirmation	Expand clones from 96-well to 6-well plates, screen by PCR and Sanger sequencing to identify correctly targeted clones. Differentiate between homozygous and heterozygous editing events. Down-select to 2–3 validated clones.	4–5 weeks
Genotype Validation	PCR + Sanger sequencing for mutation confirmation. TA cloning sequencing to confirm homozygous vs. heterozygous status. Confirmation of intended mutation without unintended indels.	2–3 weeks
Off-Target Analysis	Bioinformatics prediction of top 5–10 off-target sites. Target site amplification and sequencing validation. Gene editing specificity confirmation.	2–3 weeks
Cell Banking and Quality Release	Establish master cell bank (MCB) and working cell bank (WCB). Complete full release testing and issue a comprehensive COA.	2–3 weeks

Deliverables

Cryopreserved point mutation cell line (≥2 clones recommendedl)
Control cell line (parental cells)
Cell viability report
sgRNA target sequences and mutation strategy documentation
Donor template sequence and construction report
Genotype confirmation data (Sanger sequencing chromatograms)
Homozygous/heterozygous status identification
PCR and sequencing validation data
Off-target effect analysis report (optional)
STR cell line authentication report
Mycoplasma testing report
Complete experimental report

Point Mutation Editing Technologies

Feature	Prime Editing	Base Editing	HDR (Homology-Directed Repair)
DSB Requirement	No	No	Yes
Editing Type	Point mutations, small insertions or deletions	Base conversions (C→T or A→G)	Any type of mutation (requires donor template)
Efficiency	Moderate–High	High	Low (<10%)
Applicable Cells	Dividing and non-dividing cells	Dividing and non-dividing cells	Mainly dividing cells
Off-Target Risk	Low	Medium	High
Donor Template	Not required (pegRNA required)	Not required	Required (ssODN or dsDNA)
PAM Restriction	Less restricted	NGG required	NGG required

Application

Clinically relevant mutation modeling
Isogenic cell line generation for target validation
Protein function and signaling pathway studies
Precision oncology research

Drug resistance mechanism studies
Targeted therapy screening and evaluation
Disease modeling and functional genomics
Next-generation drug discovery

Oncology Research Areas

Our point mutation cell line construction services support a broad spectrum of oncology research by providing precisely engineered cellular models harboring clinically relevant mutations across diverse cancer types. These models enable researchers to recapitulate resistance mechanisms, validate drug targets, and investigate oncogenic driver mutations in physiologically relevant contexts. Alfa Cytology's platform is adaptable to virtually any tumor cell line of interest, empowering your research across the full spectrum of oncology disciplines, including but not limited to:

Ready to advance your oncology research with our point mutation cell line construction services? Whether your project requires a clinically relevant resistance mutation cell line for drug screening or an isogenic cell pair for target validation, Alfa Cytology is fully equipped to assist. Please don't hesitate to contact us to discuss your specific point mutation cell line needs and discover how our expertise can accelerate your oncology research programs.

Reference

Hedwig V, et al. Engineering aptamer dimers (apdimers) for optimization of synthetic riboswitches. Nucleic Acids Res. 2026;54(13).

For research use only.

Solutions

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.